Loading
Life sciences · Review
Neurology Perspectives · July 23, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes evidence that visuoperceptual and visuospatial alterations are frequent and clinically relevant symptoms in neurodegenerative diseases including Alzheimer disease, multiple sclerosis, and Lewy body dementia. The review emphasizes the value of detecting these deficits for differential diagnosis, prognosis assessment, and disease progression monitoring, but provides no new primary evidence or quantitative synthesis.
Narrative review. Patients with neurodegenerative diseases including Alzheimer disease, multiple sclerosis, and Lewy body dementia seen in neurology and neuropsychology practice.
Approximately 70% of patients with Lewy body dementia are estimated to present visuoperceptual deficits during the course of the disease Visuoperceptual and visuospatial alterations are frequent and clinically relevant symptoms in Alzheimer disease, multiple sclerosis, and Lewy body dementia
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize visuoperceptual and visuospatial deficits as frequent and clinically relevant symptoms warranting early assessment in neurodegenerative disease patients. Detection of these alterations can support differential diagnosis, prognostic assessment, and individualized treatment planning.
A narrative review synthesizing evidence on visuoperceptual deficits across neurodegenerative diseases, identifying clinical relevance for diagnosis and prognosis but containing no primary research data or comparative evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize visuoperceptual and visuospatial deficits as frequent and clinically relevant symptoms warranting early assessment in neurodegenerative disease patients. Detection of these alterations can support differential diagnosis, prognostic assessment, and individualized treatment planning.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction There is growing evidence suggesting that alterations in higher-level visual processing are a frequent and clinically relevant symptom in such neurodegenerative diseases as Alzheimer disease, multiple sclerosis, and Lewy body dementia. Some 70% of patients with Lewy body dementia are estimated to present visuoperceptual deficits during the course of the disease. Development. This text summarises the most common visuoperceptual and visuospatial alterations associated with neurodegenerative diseases commonly seen in neurology and neuropsychology practice, highlighting some of the most widely used neuropsychological tests for their detection. Moreover, it emphasises the relevance of these alterations not only for the initial and differential diagnosis of such conditions but also for predicting patients' prognosis and clinical progression across the different stages of the disease. Conclusions Future research should focus on developing new cognitive assessment tools that integrate current advances in the understanding of higher-level visual processing and neurodegenerative diseases. Early, accurate identification of visuoperceptual and visuospatial deficits is not only essential for early and differential diagnosis but can also provide valuable information about disease progression and help guide more personalised therapeutic interventions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.